JP2020535184A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020535184A5 JP2020535184A5 JP2020517843A JP2020517843A JP2020535184A5 JP 2020535184 A5 JP2020535184 A5 JP 2020535184A5 JP 2020517843 A JP2020517843 A JP 2020517843A JP 2020517843 A JP2020517843 A JP 2020517843A JP 2020535184 A5 JP2020535184 A5 JP 2020535184A5
- Authority
- JP
- Japan
- Prior art keywords
- expression vector
- human subject
- hvegf
- use according
- pyroglutamylation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023077454A JP2023113641A (ja) | 2017-09-27 | 2023-05-09 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762564095P | 2017-09-27 | 2017-09-27 | |
| US62/564,095 | 2017-09-27 | ||
| US201762574657P | 2017-10-19 | 2017-10-19 | |
| US62/574,657 | 2017-10-19 | ||
| US201762579682P | 2017-10-31 | 2017-10-31 | |
| US62/579,682 | 2017-10-31 | ||
| US201862632812P | 2018-02-20 | 2018-02-20 | |
| US62/632,812 | 2018-02-20 | ||
| PCT/US2018/052855 WO2019067540A1 (en) | 2017-09-27 | 2018-09-26 | TREATMENT OF OCULAR DISEASES WITH A TOTALLY HUMAN POST-TRANSLATIONAL MODIFICATION ANTI-VEGF FAB |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077454A Division JP2023113641A (ja) | 2017-09-27 | 2023-05-09 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020535184A JP2020535184A (ja) | 2020-12-03 |
| JP2020535184A5 true JP2020535184A5 (enExample) | 2021-09-30 |
| JP7685833B2 JP7685833B2 (ja) | 2025-05-30 |
Family
ID=65903176
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020517843A Active JP7685833B2 (ja) | 2017-09-27 | 2018-09-26 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
| JP2023077454A Pending JP2023113641A (ja) | 2017-09-27 | 2023-05-09 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023077454A Pending JP2023113641A (ja) | 2017-09-27 | 2023-05-09 | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂによる眼疾患の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20200277364A1 (enExample) |
| EP (1) | EP3687464A4 (enExample) |
| JP (2) | JP7685833B2 (enExample) |
| KR (2) | KR20250040754A (enExample) |
| AU (2) | AU2018342094B2 (enExample) |
| CA (1) | CA3076905A1 (enExample) |
| IL (1) | IL273403A (enExample) |
| SG (1) | SG11202002396TA (enExample) |
| WO (1) | WO2019067540A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013342275B2 (en) | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| IL262207B2 (en) | 2016-04-15 | 2026-01-01 | Univ Pennsylvania | Preparations for the treatment of wet age-related macular degeneration |
| CA3086045A1 (en) | 2017-12-19 | 2019-06-27 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| US12558434B2 (en) | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| EP3920950A1 (en) * | 2019-02-08 | 2021-12-15 | CureVac AG | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
| EP4667578A3 (en) * | 2019-04-03 | 2026-04-01 | REGENXBIO Inc. | Gene therapy for eye pathologies |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| CN110423281B (zh) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
| CA3149401A1 (en) | 2019-08-26 | 2021-03-04 | Stephen Joseph Pakola | Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab |
| WO2021071835A1 (en) | 2019-10-07 | 2021-04-15 | Regenxbio Inc. | Adeno-associated virus vector pharmaceutical composition and methods |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| US20230201371A1 (en) * | 2020-03-19 | 2023-06-29 | Clearside Biomedical, Inc. | Compositions and methods for treating ocular disorders |
| MX2023001109A (es) | 2020-07-27 | 2023-04-24 | Anjarium Biosciences Ag | Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas. |
| EP4225381A1 (en) * | 2020-10-07 | 2023-08-16 | RegenxBio Inc. | Formulations for suprachoroidal administration such as formulations with aggregate formation |
| IL303317A (en) | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| MX2023008826A (es) | 2021-02-01 | 2023-09-15 | Regenxbio Inc | Terapia génica para lipofuscinosis neuronal ceroidea. |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| KR20240053668A (ko) * | 2021-09-18 | 2024-04-24 | 스카이라인 테라퓨틱스 리미티드 | Wet-AMD의 유전자 치료를 위한 AAV |
| CN116925234B (zh) * | 2022-04-02 | 2024-05-31 | 合肥星眸生物科技有限公司 | 一种编码抗vegf-a和ang-2双特异性抗体的aav载体 |
| EP4593955A1 (en) | 2022-09-30 | 2025-08-06 | RegenxBio Inc. | Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6943153B1 (en) * | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US20070202186A1 (en) * | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
| EA201190273A1 (ru) * | 2009-05-28 | 2012-12-28 | Глаксо Груп Лимитед | Комбинация антагониста tnf-альфа и антагониста vegf для применения в лечении или предупреждении заболеваний глаз |
| RU2567639C2 (ru) * | 2009-06-17 | 2015-11-10 | АббВай Биотерапеутикс Инк., | Антитела против vegf и их применения |
| EP2559443A1 (en) * | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
| TWI698240B (zh) * | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| EP3043836B1 (en) * | 2013-09-11 | 2023-05-10 | Neurotech USA, Inc. | Encapsulated cell therapy cartridge |
| US10064752B2 (en) * | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| CN108778330A (zh) * | 2016-01-08 | 2018-11-09 | 科尼尔赛德生物医学公司 | 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置 |
| IL262207B2 (en) * | 2016-04-15 | 2026-01-01 | Univ Pennsylvania | Preparations for the treatment of wet age-related macular degeneration |
| JP2019515027A (ja) * | 2016-04-15 | 2019-06-06 | レジェンクスバイオ インコーポレーテッド | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| US12558434B2 (en) * | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| US20230201371A1 (en) * | 2020-03-19 | 2023-06-29 | Clearside Biomedical, Inc. | Compositions and methods for treating ocular disorders |
-
2018
- 2018-09-26 CA CA3076905A patent/CA3076905A1/en active Pending
- 2018-09-26 KR KR1020257008245A patent/KR20250040754A/ko active Pending
- 2018-09-26 WO PCT/US2018/052855 patent/WO2019067540A1/en not_active Ceased
- 2018-09-26 US US16/645,877 patent/US20200277364A1/en not_active Abandoned
- 2018-09-26 SG SG11202002396TA patent/SG11202002396TA/en unknown
- 2018-09-26 JP JP2020517843A patent/JP7685833B2/ja active Active
- 2018-09-26 EP EP18862872.1A patent/EP3687464A4/en active Pending
- 2018-09-26 KR KR1020207011989A patent/KR20200060456A/ko not_active Ceased
- 2018-09-26 AU AU2018342094A patent/AU2018342094B2/en active Active
-
2020
- 2020-03-18 IL IL273403A patent/IL273403A/en unknown
-
2023
- 2023-05-09 JP JP2023077454A patent/JP2023113641A/ja active Pending
- 2023-07-27 US US18/360,073 patent/US20240254214A1/en not_active Abandoned
-
2025
- 2025-02-26 US US19/064,049 patent/US20250320287A1/en active Pending
- 2025-05-02 AU AU2025203154A patent/AU2025203154A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7544766B2 (ja) | 片頭痛の治療または予防法 | |
| US20220162296A1 (en) | Personalized treatment of ophthalmologic diseases | |
| TWI755763B (zh) | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 | |
| US8758748B2 (en) | Anti-angiogenic therapy | |
| JP2010528047A5 (enExample) | ||
| AU2015204503B2 (en) | Novel vaccines against HPV and HPV-related diseases | |
| AU2017299581B2 (en) | Humanized monoclonal antibodies that target ve-ptp (hptp-β) | |
| CN109071656A (zh) | 检查点调节物拮抗剂 | |
| HUE032654T2 (en) | scFv antibodies that cross the epithelial and / or endothelial layers | |
| TW201726741A (zh) | Ctla4結合劑 | |
| CA3025258C (en) | Use of sirolimus to treat exudative age-related macular degeneration with persistent edema | |
| CN107635580A (zh) | 治疗眼病的方法 | |
| WO2007120828A1 (en) | Use of il-i antibodies for treating ophthalmic disorders | |
| Touchard et al. | Non-viral ocular gene therapy, pEYS606, for the treatment of non-infectious uveitis: Preclinical evaluation of the medicinal product | |
| TW202237181A (zh) | 治療眼部疾病之方法 | |
| EP4419143A1 (en) | Methods of use and administration of encapsulated cells | |
| KR20220002972A (ko) | 변형 항 pd-l1 항체 및 신경변성 질환 치료 방법 및 용도 | |
| Pitcher et al. | Suprachoroidal delivery of investigational ABBV-RGX-314 for neovascular AMD: results from the phase II AAVIATE® study | |
| TW201806970A (zh) | 嵌合抗原受體、及其利用 | |
| JP2020518641A (ja) | Ａｐｌｎｒアンタゴニストおよびｖｅｇｆ阻害剤によって眼疾患を治療する方法 | |
| Matei et al. | What’s coming in therapies for diabetic retinopathy | |
| CN118791612A (zh) | 靶向cd26的抗原结合蛋白及其药物应用 | |
| Barakat et al. | Neovascular AMD: Where do we go from here? | |
| NANGREJO et al. | SHORT TERM COMPLICATIONS OF INTRAVITREAL INJECTION OF BEVACIZUMAB. | |
| NZ746655A (en) | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |